Section Arrow
Quote
FTRE.NASDAQ
- Fortrea Holdings
Quotes are at least 15-min delayed:2025/06/03 23:17 EDT
Last
 4.63
+0.5 (+12.11%)
Day High 
4.63 
Prev. Close
4.13 
1-M High
7.99 
Volume 
3.04M 
Bid
4.41
Ask
4.63
Day Low
3.97 
Open
4.07 
1-M Low
3.97 
Market Cap 
373.77M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.26 
20-SMA 4.8 
50-SMA 5.82 
52-W High 28.41 
52-W Low 3.97 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.79/-2.82
Enterprise Value
1.48B
Balance Sheet
Book Value Per Share
9.49
Cash Flow
Cash Flow Yield
0.44
Income Statement
Total Revenue
2.70B
Operating Revenue Per Share
34.05
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed：2025/06/03 23:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.